India’s Concord Biotech saw a 24.6% surge in its share prices to Rs 923 on Friday. With the biopharma company’s IPO initially priced at Rs 741 rupees, its valuation is now at $1.16bn. The IPO was made up of 20.9 million shares from existing stakeholders, and subscribed 24.87 times as of the final day of bidding in August.
Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News